SHENZHEN, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product's review process for marketing approval in the AD indication.Impressive phase III trial data in ADIts Priority Review is expected to accelerate its NDA approvalRuxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product's expansion into multiple therapeutic areas.Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD.Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001).Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated.Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date.Building an integrated AD solution,strengthening Dermavon’s leadership in dermatologyAD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care.Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's market competitiveness and brand influence in the field of skin health.More Information About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurarCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司 （"康哲药业"）欣然宣布，旗下德镁医药有限公司（"德镁医药"，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市，详见康哲药业日期为2025年4月22日发布的公告）已于2026年2月24日获得中国国家药品监督管理局（NMPA）受理磷酸芦可替尼乳膏（"产品"）轻中度特应性皮炎（"AD"）的新药上市许可申请（NDA）。产品拟用于其他外用药控制不佳或不建议使用时，非免疫功能受损的2岁及以上儿童和成人轻中度特应性皮炎的局部短期和非持续性慢性治疗。且该项NDA因"符合儿童生理特征的儿童用药品新品种、剂型和规格"，已获得NMPA药品审评中心批准纳入优先审评品种名单，有望加快产品AD适应症上市审评进程。特应性皮炎III期临床数据亮眼，优先审评加速上市磷酸芦可替尼乳膏已于2026年1月获得NMPA批准上市，成为中国批准的首款且唯一用于白癜风治疗的靶向药。此次增加AD适应症NDA获受理，是产品向多治疗领域拓展的关键里程碑。磷酸芦可替尼乳膏已在轻中度AD的一项随机、双盲、安慰剂对照中国三期药物临床研究取得积极结果：- 疗效优异：产品成功达到主要终点，即使用产品治疗8周，达到研究者整体评估（IGA）评分为0或1分，且较基线改善≥2分的受试者比例，显著高于安慰剂（63.0% vs 9.2%，P<0.001）。关键次要终点，磷酸芦可替尼乳膏治疗8周，达到湿疹面积及严重程度指数评分较基线至少改善75%（EASI 75）的受试者比例亦显著优于安慰剂（78.0% vs 15.4%，P<0.001）。- 安全性良好：治疗期出现的不良事件（TEAE）的严重程度大多数为轻度或中度，未发生导致研究药物用药终止的TEAE，整体安全耐受性良好。此外，该项NDA已获批纳入优先审评品种名单。根据NMPA相关规定，适用优先审评审批程序的上市注册申请的审评时限由常规程序的200日大幅缩短为130日，审评时限将得到显著缩短，这将有望加速磷酸芦可替尼乳膏AD适应症的上市进程，早日惠及广大患者。构建特应性皮炎综合方案，强化皮肤领域竞争实力AD是一种慢性、复发性、炎症性的皮肤疾病，临床主要表现为皮肤干燥、慢性湿疹样皮损和明显瘙痒，可能严重影响患者的生活质量。据估算，2024年中国特应性皮炎患者超过5,400万人，基于SCORAD评分，轻中度特应性皮炎的占比为98%，即超过5,250万患者[1]。外用药物是AD最基本的治疗方法。传统外用药物如外用糖皮质激素（TCS）及外用钙调神经磷酸酶抑制剂（TCIs）有长期用药的不良反应或疗效有限的临床痛点，临床亟需新的治疗选择。德镁医药已针对AD构建了全方位的"治疗+护理"综合解决方案，除局部外用制剂-磷酸芦可替尼乳膏（轻中度AD）外，还包括注射用生物制剂-柯美奇拜单抗注射液-MG-K10（中重度AD）、口服小分子靶向药-CMS-D001（中重度AD）、日常修护-禾零舒缓产品系列，满足AD患者从治疗到日常护理的管理需求。同时，此次增加AD适应症NDA获受理，将进一步强化德镁医药在皮肤治疗领域的战略布局，并与现有处于商业化阶段的创新药益路取（替瑞奇珠单抗注射液）、独家药喜辽妥（多磺酸粘多糖乳膏），以及系列在研创新药和皮肤学级护肤品等在专家网络与市场资源等方面产生协同，提升德镁医药在皮肤健康领域的市场竞争力与品牌影响力。关于磷酸芦可替尼乳膏的更多信息磷酸芦可替尼乳膏（Opzelura(R)）是Incyte开发的选择性JAK1/JAK2抑制剂芦可替尼制成的一种创新型乳膏。在中国，磷酸芦可替尼乳膏获批用于治疗12岁及以上儿童和成人患者伴面部受累的非节段型白癜风。在美国，磷酸芦可替尼乳膏是经美国食品和药物管理局（FDA）批准的首款局部JAK抑制剂，可用于局部治疗12岁及以上患者的非节段型白癜风；及其他外用药控制不佳或不建议使用时，非免疫功能受损的2岁及以上儿童和成人轻中度特应性皮炎的局部短期和非持续性慢性治疗[2]。在欧洲，磷酸芦可替尼乳膏被批准用于治疗成年及12岁及以上青少年面部受累的非节段型白癜风[3]。康哲药业于2022年12月2日，通过德镁医药的附属公司与Incyte就磷酸芦可替尼乳膏订立合作和许可协议（"许可协议"），获得在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及东南亚十一囯（"区域"）研发、注册及商业化产品的独家许可权利，以及在区域内生产产品的非独家许可权利。德镁医药的附属公司已将磷酸芦可替尼乳膏除中国大陆外的其他区域的相关权利再许可予康哲药业（不包括德镁医药及其附属公司）。Incyte拥有磷酸芦可替尼乳膏全球开发和商业化权利，在美国及欧洲以Opzelura(R)的名称销售。Opzelura(R)和Opzelura(R)标识是Incyte的注册商标。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。参考文献/资料1.数据来自灼识咨询报告2.FDA批准信息可在Incyte官网查询，网址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3.EMA批准信息可在Incyte官网查询，网址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和-医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2026年2月24日，康希诺生物（688185.SH/06185.HK）宣布，公司自主研发的ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体）——曼海欣(R)扩大适用人群的补充申请已正式获得国家药品监督管理局批准。此次获批后，曼海欣(R)适用于3月龄至6周岁（83月龄）的婴幼儿及儿童，用于预防由A、C、Y、W135群脑膜炎奈瑟菌引起的流行性脑脊髓膜炎（以下简称"流脑"）。此次曼海欣(R)扩龄获批，具有重要的公共卫生和商业发展意义。一方面，在我国现行免疫规划程序中，6岁是入学前流脑疫苗接种"最后一针"的重要节点，长期以来，国内针对3岁以上儿童的多价流脑结合疫苗选择相对有限。曼海欣(R)此次扩龄获批，为学龄期儿童提供了四价流脑多糖结合疫苗接种选择，有助于填补儿童流脑防控在关键年龄阶段的保护空白，进一步完善我国流脑免疫屏障。另一方面，适用人群范围的扩大，将有助于曼海欣(R)进一步释放产品潜力，提升商业化空间，并为该产品在国际市场的推广与布局奠定更为坚实的基础。值得一提的是，康希诺生物日前已发布2025年度业绩预告，全年营收预计10.4–10.8亿元，同比增长22.88%-27.61%；归母净利润预计2450万–2900万元，将实现扭亏为盈。同时，公告明确指出，"公司持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫苗曼海欣(R)收入保持持续增长"。这也意味着康希诺生物已进入创新疫苗商业化收获期。依托独家技术平台、领先优势及加速的国际化布局，曼海欣(R)扩龄不仅巩固了市场竞争力，也为康希诺生物的可持续增长注入新的动力。随着产品覆盖和国际拓展的推进，公司长期价值将开启更广阔的发展空间。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2026年新版《道路机动车辆生产企业准入审查要求》中，仿真验证能力被作为强制性关键要素写入准入审查要求，国产仿真平台迎来巨大的市场利好，进一步推动了智驾产业链加速向"自主可控"迈进。在此背景下，五一视界宣布旗下51Sim下一代智驾仿真平台 SimOne 4.0 已于近日成功完成在摩尔线程旗舰级AI训推一体全功能GPU MTT S5000上的系统性适配与深度优化。从大模型感知挖掘、4DGS模型训练到4DGS仿真推理和合成数据生成，双方强强联手，实现了国产算力与端到端智能驾驶仿真体系的完整打通，正式开启了物理AI智驾领域高置信度闭环仿真与合成数据的全栈国产化新篇章,为应对新规下的严苛验证需求提供了坚实的国产底座。算力底座的"跨代式"追赶随着端到端智驾收敛到VLA和世界模型两条路线，基于海量Log数据的高置信度闭环仿真和合成数据已成为提升算法长尾场景处理能力的关键命题。仿真效率的上限，往往取决于基础一硬件的规格。在很长一段时间里，高端GPU市场几乎被海外巨头垄断，但五一视界与摩尔线程的最新合作成果显示，这一格局正在发生微妙的变化。SimOne 4.0已完成与摩尔线程MTT S5000的深度适配。MTT S5000是专为大模型训练、推理及高性能计算而设计的全功能GPU智算卡，基于第四代MUSA架构"平湖"打造。其单卡AI算力（稠密）最高可达1000 TFLOPS，配备80GB显存，显存带宽达到1.6TB/s，卡间互联带宽为784GB/s，完整支持从FP8到FP64的全精度计算。基于SimOne 4.0实现7个周视摄像头4DGS场景重建效果在实测数据中，MTT S5000展现出了足以抗衡甚至部分超越国际主流竞品的硬实力。数据显示，MTT S5000在FP32、FP16及INT8等关键精度上实现了约1.47倍的性能增长，FP64双精度算力领先幅度约1.48倍。更值得关注的是其搭载的MTLink技术，使得卡间带宽提升约30%。MTT S5000凭借FP8提升训推效率、FP64保障计算精准、光线追踪实现高保真渲染，以自主可控的强劲底层算力，为智能驾驶提供安全、高效、可靠的核心国产算力支撑。场景实测：在复杂博弈中验证"真功夫"硬件参数的领先，最终需要在真实的算法场景中落地。在SimOne 4.0的大模型感知挖掘功能中，双方针对Qwen3-VL多模态大模型进行了深度调优。实测结果令人惊喜：无论是在8B模型还是更复杂的30B MoE架构下，MTT S5000在"预填充（Prefill）"阶段的首字响应速度（TTFT）均优于国际主流竞品，优势最高扩大至14%，且在10并发的高压环境下依然保持了稳健的吞吐量。而在更考验训练和推理能力的4DGS（4D高斯泼溅）领域，基于51Sim入选AAAI 2026的LidarPainter技术，国产算力同样经受住了考验。目前测试数据显示，在训练端，MTT S5000展现出比肩国际主流竞品的强劲性能，仅需2.5小时即可完成一个真实Clip场景的高质量重建；在推理端，面对单Clip包含1600万个高斯点的超大模型负载，MTT S5000成功实现了11路摄像头加1路激光雷达的实时闭环仿真，呈现出像素级的高保真效果。这证明了国产显卡在处理复杂光影与动态物体还原时，已经具备了生产力级别的属性,能够胜任准入审查中要求的极端工况与边界条件验证。这种高保真物理场景的重建能力，同样可迁移至具身智能机器人的空间感知与操作训练中。基于LidarPainter 技术生成高真实度新视角图像隐形护城河：构建"芯片+系统"的通用底座如果说高性能GPU的适配是攻克了"最难的骨头"，那么对国产基础软硬件生态的全面覆盖，则是五一视界构筑的一条安全护城河,也是响应国家信创战略、满足敏感行业准入要求的关键。除了图形计算领域，五一视界已悄然完成了对主流国产芯片架构的全线互认。在CPU层面，无论是基于ARM架构的华为鲲鹏、飞腾，还是基于x86架构的海光、兆芯，五一视界旗下的51Aes、51Sim等核心产品均已实现流畅部署。特别是通过华为鲲鹏技术认证并加入"鲲鹏展翅"计划，进一步夯实了其在国产服务器端的运行稳定性。在操作系统层面，为了彻底摆脱对非国产发行版的依赖，五一视界将适配工作下沉至系统内核，先后完成了与麒麟软件（银河麒麟高级服务器操作系统）及统信软件（UOS）的适配认证。这一举措意味着，对于政府、能源等有着严苛信创要求的敏感行业客户而言，他们可以选择从芯片到底层操作系统到上层应用全链路自主可控的数字孪生解决方案,从容应对日益严格的合规性审查,构建起一个不仅服务于智能驾驶，更能广泛赋能于人形机器人等具身智能终端的国产化通用基础设施。中国科技企业"国产自主可控"已经崛起从携手摩尔线程在高端算力上撕开缺口，到打通华为鲲鹏、麒麟等操作系统的生态脉络，再到积极响应新版准入审查要求提供合规的仿真验证能力，五一视界的这一系列动作表明，中国企业的"国产自主可控"正在发生量变和质变，正在缓缓崛起。这不再是简单的参数对标，而是产业生态的战略闭环。SimOne 4.0的表现证明，国产软硬件方案已经迈过了"能用"的门槛，正式进入了高精度、高负载任务的"好用"阶段。随着算法与算力的深度融合，以及政策法规对仿真验证能力的强制加持，一个繁荣的、自主可控的物理AI生态底座正在逐步成型，为中国智能驾驶产业的独立发展保驾护航,也为具身智能机器人等新兴领域的国产化落地铺平了道路。基于SimOne 4.0 的4DGS闭环仿真 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 23, 2026 - (ACN Newswire via SeaPRwire.com) – During the Year of the Horse Spring Festival, momentum in the "Hard Tech" sector continued to surge, with the humanoid robotics industry becoming a market focal point following its stellar performance on the Spring Festival Gala stage. Shoucheng Holdings (0697.HK) has emerged as a core target for post-holiday capital market positioning due to a series of heavy-hitting moves. These include the operational launch of the Taozhu New Creation Hub - a comprehensive robotics technology experience, sales, maintenance, and service center—followed by the dual boost of Spring Festival Gala exposure and New Year's Eve livestreaming conversions. Coupled with the positive signal of continuous recent share buybacks, the company’s solid industrial layout and clear earnings growth are expected to trigger a formal valuation recovery.By establishing a closed-loop of "Offline Landing + Strategic Investment + Traffic Conversion + Buyback Support," Shoucheng Holdings has not only demonstrated its deep layout in the robotics track but has also provided the capital market with a high-certainty investment logic through concrete industrial actions and capital behavior. The window for valuation recovery has officially opened.I. Grand Opening of the Offline Complex: Solidifying the Foundation for MonetizationAs the traffic dividends from the Spring Festival Gala and livestreaming were released, Shoucheng Holdings officially launched Taozhu New Creation Hub, its flagship robotics technology retail brand. This complex captures the core of the offline smart consumption track and injects deterministic growth into Shoucheng’s performance. It serves as a solid physical carrier to convert gala traffic and livestreaming orders, marking a new stage in Shoucheng’s full-chain service layout for offline robotics commercial scenarios.Integrated Ecosystem: The Hub constructs an "Experience + Sales + After-sales + Investment" full-model ecosystem."Store-Factory" Innovation: Utilizing an innovative "front-store, back-factory" layout, it includes a robotics maintenance and repair workshop created in collaboration with Accelerated Evolution to provide one-stop services.Market Validation: With an exhibition area exceeding 400 square meters, the Hub serves as a core scenario for investee companies to implement technology and validate market demand.Strategic Store Matrix:Wangfujing APM Store: Located in a premier trendy commercial district, focusing on "Trend Tech + First-Store Economy," targeting consumers aged 18–35.Capital Airport T2 Store: Situated in a core transportation hub with 35 million annual passengers, targeting the "40-minute pre-boarding decision" window with portable and practical smart products.This layout is a key execution of Shoucheng’s "Capital + Scenario + Ecosystem" strategy. By capturing consumer demand through digital means, it provides investee companies with valuable data for product iteration, forming a virtuous cycle of "Industry + Consumption + Maintenance".II. Dominance of the Gala Trio: National-Level Endorsement of Ecosystem StrengthThe Year of the Horse Spring Festival Gala featured a humanoid robot cluster performance as its most high-tech highlight. Among the four core robotics companies featured, three - Unitree Robotics, NOETIX Robotics, and Galbot - are Shoucheng Holdings' portfolio companies. This dominant presence provides national-level brand endorsement for the offline scenarios.The three portfolio companies demonstrated world-class capabilities across core tracks:Unitree Robotics: Deployed a 16-robot formation in the program "Wu BOT," performing high-difficulty martial arts. It achieved world-firsts in continuous parkour flips and rapid maneuvers (up to 4m/s) using self-developed dexterous hands.NOETIX Robotics: Earned the title of "Exclusive Bionic Humanoid Robot Partner" for the gala. Its "Xiaowantong N2" and "Xiaobumi" consumer products displayed lifelike facial expressions and synchronized breathing movements, signaling the acceleration of robots entering the home.Galbot: Debuted as the "Designated Embodied AI Model Robot". Its robot, "Xiao Gai," autonomously performed real-time tasks—such as picking up glass shards and folding clothes—driven by its "AstraBrain" Embodied AI model.This collective appearance is a result of Shoucheng's long-term deep layout, building a complete investment matrix across core components, whole units, and "intelligent brains".III. New Year's Eve Live-streaming: Immediate Traffic MonetizationOn the night of the Gala, Shoucheng Holdings launched the "PoBiren (Barrier-Breaker) Initiative" Live-streaming event, becoming the only industrial investor in the sector to achieve immediate traffic conversion. This successfully closed the loop of "Offline Landing - Stage Exposure - Online Traffic - Order Conversion".Solving Pain Points: The livestream addressed the "unreachable" nature of online consumption through product demonstrations and professional technical interpretations.Seamless Integration: It linked online orders to the Taozhu New Creation Hub for offline delivery and maintenance.Professional Branding: By sharing industry trends from an investor's perspective, Shoucheng deepened consumer trust and solidified its leadership in hard tech investment.ConclusionShoucheng Holdings has achieved a triple breakthrough in national exposure, immediate traffic conversion, and offline operations. Under the resonance of these multiple benefits and continued buybacks, the logic for both valuation and performance enhancement is further strengthened, allowing Shoucheng to lead the hard tech investment track and provide long-term stable returns to investors. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – February 22, Galaxy Payroll Group Limited (NASDAQ: GLXG) (“Galaxy” or the “Company”), a Nasdaq-listed human resources solutions provider, today announced that it has formally renewed a five-year strategic cooperation agreement with NIKE China Holding HK Limited (Macau Branch) (“Nike Macau Branch”).Five-Year Renewal with Comprehensive HR Service CoveragePursuant to the agreement, the renewed cooperation term will commence on December 1, 2025 and continue through November 30, 2030. During this period, Galaxy will continue to provide Nike Macau Branch with a comprehensive suite of human resources outsourcing services, including local payroll processing, attendance and leave management, social security and tax compliance filings, as well as advisory services relating to labor regulations and employment policies.This integrated service model is designed to enable Nike Macau Branch to focus on its core retail and brand operations while enhancing overall organizational efficiency and compliance management.Strategic Renewal Reflects Client Confidence and Enhances Revenue VisibilityThe renewal marks an important milestone in the long-standing relationship between the parties and reflects the continued trust placed in Galaxy’s professional capabilities, compliance standards, and service delivery quality by a leading international brand.The execution of a multi-year agreement is expected to enhance the Company’s revenue visibility and cash flow stability over the next five years, further aligning with its capital markets strategy of building a high-quality, resilient, and sustainable business model. While the agreement provides for long-term cooperation, actual results may vary and remain subject to market and operational conditions.Local Expertise and Scalable Service Infrastructure as Core Competitive AdvantagesSince its establishment in 2013, Galaxy has focused on the Hong Kong and Macau markets while progressively expanding its cross-regional service capabilities. The Company has developed deep expertise in Hong Kong and Macau labor laws, taxation, and social security regulations, forming a strong local compliance foundation.Through a service framework that combines standardized operational processes with customized solutions, Galaxy delivers consistency and scalability across its client base. Its proprietary payroll and attendance management platform enhances operational efficiency while supporting data security and business continuity, serving as a key differentiator in attracting and retaining multinational enterprise clients.Throughout prior phases of cooperation, Galaxy has supported Nike Macau Branch in navigating complex employment and compliance environments. The Company’s solutions have demonstrated reliability in accuracy, responsiveness, and risk control, providing a solid foundation for this long-term renewal.Looking Ahead: From Service Delivery to Value Co-CreationEntering the new cooperation cycle, Galaxy intends to further optimize payroll workflows and intelligent attendance systems within the existing service framework. Through enhanced data integration and periodic management reporting, the Company aims to support the client’s ongoing efforts toward standardized and digitalized human resource management.The parties have also agreed to retain flexibility to expand the scope of services through supplemental agreements, enabling the partnership to evolve in alignment with the client’s business development.The renewal of this five-year strategic agreement not only represents long-term recognition of Galaxy’s professional value, but also underscores the sustainability of its business model. It is expected to further strengthen the Company’s brand presence in the Hong Kong, Macau, and broader Asia-Pacific human resources outsourcing markets, while serving as a replicable benchmark case for multinational retail, sports, and consumer brands.As global enterprises increasingly prioritize compliance efficiency, cost optimization, and organizational resilience, Galaxy continues to leverage its localized expertise, robust service infrastructure, and high-quality client base to build sustainable long-term growth momentum.The Company’s management commented: “We will continue to place service capability at the core of our growth strategy, deepen strategic cooperation with existing high-quality clients, and proactively expand relationships with multinational and regional enterprises that offer long-term value, with the goal of delivering steady and sustainable returns to our shareholders.”Contact informationJune TuoTel: (852) 5983-9260Phone: (86)1392-3804-279Intelligent Joy Limited Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2026年2月22日, 纳斯达克上市公司迦里仕人才集团有限公司（Galaxy Payroll Group Limited，NASDAQ: GLXG，以下简称“迦里仕人才”）宣布，已与耐吉中国控股香港有限公司澳门分公司（NIKE China Holding HK Limited (Macau Branch)，以下简称“耐吉澳门分公司”）正式续签为期五年的战略合作协议。合作再延五年，服务范围全面覆盖核心HR职能根据协议，双方合作期限自2025年12月1日起至2030年11月30日止。在此期间，迦里仕人才将继续为耐吉澳门分公司提供涵盖本地薪资发放、考勤与休假管理、社保及税务合规申报，以及劳动法规与用工政策咨询在内的一站式人力资源外包服务。该合作模式有效支持耐吉澳门分公司聚焦其核心零售与品牌运营，提升整体组织效能。战略续约彰显客户高度信任，强化收入稳定性此次续约不仅是双方合作关系迈入新阶段的重要标志，更体现了国际头部品牌对迦里仕人才专业能力、合规水平及长期服务交付质量的高度认可。中长期合约的签署显著增强了公司未来五年收入的可预测性与现金流稳定性，进一步契合其打造高质量、抗周期业务模型的资本市场战略。本地化能力构筑核心壁垒，服务体系持续进化自2013年成立以来，迦里仕人才始终深耕港澳市场，并逐步拓展跨区域服务能力。公司凭借对香港及澳门劳动法、税务及社保政策的深度掌握，建立起扎实的本地合规能力；同时依托标准化流程与定制化方案相结合的服务体系，确保交付的一致性与可扩展性。其自主开发的薪资与考勤管理平台，在提升运营效率的同时有效保障数据安全与业务连续性，成为吸引并维系跨国企业客户的关键优势。在过往合作中，迦里仕人才已多次协助耐吉澳门分公司应对复杂用工环境下的合规挑战，其解决方案在准确性、响应速度及风险控制方面均获得充分验证，为本次长期续约奠定了坚实基础。展望未来：从服务交付迈向价值共创展望新合作周期，迦里仕人才将在现有服务框架基础上，持续优化薪资管理流程与智能考勤系统，并通过数据整合与定期管理报表，助力客户推进人力资源管理的规范化与数字化转型。双方亦约定保留通过补充协议灵活拓展服务范围的机制，确保合作节奏与客户业务发展动态同步。此次五年期战略合作的续签，不仅是对迦里仕人才专业价值的长期肯定，更是对其商业模式可持续性的有力印证。它将进一步巩固公司在港澳及亚太人力资源外包市场的品牌影响力，并为服务更多跨国零售、体育及消费品牌提供可复制的标杆案例。在全球企业日益重视合规效率、成本优化与组织韧性的背景下，迦里仕人才正凭借其深厚的本地化经验、稳健的服务体系与高粘性的优质客户基础，稳步构建长期增长动能。公司管理层表示：“我们将继续以服务能力为核心驱动力，深化与现有优质客户的战略合作，同时积极拓展更多具有长期价值的跨国及区域性企业客户，持续为股东创造稳健、可持续的回报。” Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2月23日，由上海实业（集团）有限公司（以下简称"上实集团"）与国泰海通证券股份有限公司（以下简称"国泰海通"）联合发起设立的沪港新兴产业基石基金（以下简称"基石基金"）正式启航，进入实质投资阶段。作为全国首支、上海市级市场化运作的证券类港股基石基金，基金目标总规模30亿港元，首期规模10亿港元，将聚焦集成电路、生物医药、人工智能上海三大先导产业，专项支持优质企业赴港上市，深化沪港金融与产业协同。服务上海战略，强化沪港联动上海市政府和上海市国资委指导设立的基石基金，是上海国资服务上海科技创新中心建设、推动重点产业高质量发展的重要举措，将紧密围绕上海前瞻的集成电路、生物医药、人工智能三大先导产业进行战略布局，通过资本市场赋能，加速本地创新企业国际化进程。同时，基金也将充分发挥香港作为国际金融中心的枢纽功能，构建"上海产业+香港资本"的高效联通机制，促进两地金融资源互补与市场互联，打造沪港合作新标杆。创新"双管理人"架构，汇聚两地专业力量基石基金在治理模式上采用创新的"双管理人"架构，由上实集团在港金融投资业务平台上实资本（香港）投资管理有限公司，和国泰海通在港资产管理平台海通国际资产管理有限公司共同担任基金管理人，并由沪港两地协同运营。这一合作架构充分融合了上实集团作为上海在港窗口企业的产业资源与香港本地的运营优势，及国泰海通在全球资本市场和跨境资产管理方面的专业能力，实现"产业+金融"、"上海+香港"的双重优势互补。通过建立完善的投资决策机制与风险控制体系，该架构既确保了基金运作符合国际标准，又保持了与本土产业生态的深度链接，为基金的长期稳健运作奠定了坚实基础。多元化投资策略，专注长期价值基石基金坚持市场化、专业化、国际化运作原则，以产业、金融双重视角，构建覆盖企业全生命周期的投资与赋能体系。通过灵活的多元化策略组合与深度投后服务，系统性支持上海三大先导产业优质企业的业务发展与价值实现。基石基金在重点参与上海三大先导产业优质企业赴港IPO的基石投资之外，还可以参与港股IPO锚定和已上市港股的配售投资，通过无锁定期策略保持基金的流动性，以保证基金投资收益；在市场大幅下跌时，也可通过二级市场方式，增持价值低估的优质公司股票；同时跟进优秀企业再融资及并购重组，助力可持续发展。基石基金将严格遵循"好赛道、好公司、好价格"的遴选标准，重点投向具备核心技术、高成长性和稳健现金流的行业领军企业。强化上海国资在港功能，构建跨境投资新平台基石基金是上实集团和国泰海通强化在港服务功能、完善跨境投资布局的关键举措之一。基石基金不仅进一步完善上海国资基金矩阵，填补国资基金在港股IPO及二级市场策略的空白，服务上海企业赴港上市"最后一公里"融资需求，助力构建"早期投资—成长期融资—公开市场上市"的完整产业投资生态；更通过上实集团和国泰海通的深度合作，强强联手、协作共赢，系统提升跨境合规、资产配置与复杂交易设计能力，进一步增强上海国资服务上海乃至国家战略的综合实力。展望：链接国际资本，赋能创新未来在全球科技创新竞争日益激烈的背景下，沪港新兴产业基石基金的实质启动，标志着上海在对接国际资本市场、服务本土创新方面迈出系统性的一步。在人民币国际化和"惠港五条"等政策红利支持下，基石基金将成为连接内地产业资本与国际金融资源的重要纽带。未来，基石基金将积极把握人民币国际化与金融市场双向开放机遇，持续促进国际资本投资上海核心产业，为上海三大先导产业企业提供全方位的资本服务，助力更多硬科技企业走向世界，为沪港融合与高质量发展贡献力量。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2026年2月2日，维昇药业于上海举办维臻高(R)（注射用隆培生长激素）获批上市投资者交流会。 该产品已于1月26日获得国家药品监督管理局批准上市。公司在会上表示，维臻高(R)被定位为具备里程碑意义的创新产品 - 不仅是首个在欧美获批用于儿童的长效生长激素，也是目前临床研究中唯一被证实在疗效上优于日制剂的长效生长激素产品。在生长激素赛道中，随着多款产品陆续纳入医保、价格体系快速下探，市场竞争格局正在发生变化。维昇药业以临床价值和技术壁垒为核心，打造差异化的高端产品路径。本次交流会由公司管理层系统介绍了产品研发逻辑、临床数据及当前阶段商业化策略的核心思路。本次会议邀请了多位合作伙伴与行业嘉宾出席，包括国妇婴主任医师余文教授、安科生物高级副总裁姚建平先生、副总裁鲍学科先生、上药控股副总经理宋潞潞女士、上海和睦家医院长宁院区执行院长刘晓龙先生等到场支持。同时，公司长期股东代表——碧沃投资合伙人柳丹先生亦出席交流，体现了核心股东对公司商业化路径与长期价值的持续认可。中信证券、东吴证券、天风证券和国海证券等多家大型券商及投资机构亦参与本次会议。一、产品内核：技术壁垒构建差异化护城河1.1 "暂时连接"技术的独特性在生长激素领域，由于技术壁垒高，实现长效化与保持活性分子的天然结构长期被视为"鱼与熊掌不可兼得"，而维臻高(R)的研发上市成功突破这一行业技术壁垒，是全球首款实现"长效化+天然结构"作用机理的长效生长激素。维昇药业首席商务官陈军在会上详细拆解了TransCon技术平台的突破：通过惰性载体（PEG）将天然结构的重组人生长激素暂时包裹和保护起来形成前药，前药在注射至皮下时没有活性，进入血液循环在，将惰性载体与生长激素暂时连接起来的TransCon连接结构在体温与生理pH值下发生自动裂解，7天内以特定的速率逐步释放出与人体自身分泌完全一致的2.2万道尔顿（22kD）、191个氨基酸的天然结构的生长激素。这一"暂时连接"机制与市面上其他长效生长激素的"永久连接"形成本质区别。陈军指出，目前已上市的其他长效生长激素均属于"生长激素类似物"——其活性分子结构已改变，分子量高达6万-9万道尔顿，远远高于天然生长激素的2.2万道尔顿。维臻高(R)进入人体内释放的活性分子与内源性生长激素的分子量、分子结构、组织分布以及药理特性相同，也是首款活性分子是"长效生长激素"而非"生长激素类似物"的长效产品。国妇婴主任医师余文教授从临床角度补充了关键细节：分子量过大的药物难以穿透致密的骨骺板，无法发挥生长激素的直接作用，也就可能直接影响疗效。维臻高(R)以内源性生长激素的"原药形式"发挥作用，是其头对头研究取得优效结果的理论依据和科学基础。1.2 说明书上的"法律证据"余文教授在交流中特别强调，在临床实践中，尤其是一款新药，经国家药监部门审评并写入药品说明书的内容，是判断药品疗效与安全性的核心法定依据，也是临床用药的权威规范标准，它构成了疗效与安全性判断的核心标准,是药品的"身份证"。维臻高(R)本次获批的产品说明书直接显示了其疗效优于每日制剂：境外临床研究结果："主要疗效终点是第52周时年化生长速率（AHV）。本品治疗52周时的AHV非劣效并优效于健豪宁(R)组。此外，本品治疗后的身高SDS较基线的增加幅度高于健豪宁(R)组。从治疗第26周至第52周试验结束时，对于AHV和身高SDS 较基线的变化，本品组都较健豪宁(R)组更显著。"中国临床研究结果："主要疗效终点是第52周AHV。本品治疗52周的AHV为 10.66cm/年，相比诺泽(R)组的AHV 9.75cm/年，统计分析结果显示达到非劣效性以及优效性，即证明了本品治疗的52周AHV优效于诺泽(R)组，与境外3期研究结果一致。此外，本品组治疗时的身高SDS较基线的增加幅度高于诺泽(R)组，也显示了优效性。从治疗第13周至第52周试验结束时， 对于AHV和身高SDS较基线的变化，本品组都较诺泽(R)组更显著。"1.3 安全性设计的双重保障分子安全性：由于维臻高(R)的活性成分与内源性生长激素结构完全一致，避免了未知分子风险；而其他长效生长激素均为"人造分子"，长期安全性存疑（辉瑞、诺和诺德曾尝试PEG永久修饰技术研发长效生长激素，但均因安全性和疗效问题终止研发）。局部安全性：注射部位无活性，避免脂肪萎缩等不良反应。陈军特别解释：其他部分长效产品将"7天剂量一次打入一个注射部位"，注射部位存在高浓度活性成分；维臻高(R)的"包裹"技术使其在皮下无活性，只在该发挥作用时才呈现活性，降低了导致脂肪细胞溶解、皮肤凹陷的可能，这是"另一个安全性优势"。更值得关注的是其长期安全性数据：维臻高(R)全球关键3期研究治疗1年的结果显示，其不良反应发生的种类与频率均与生长激素日制剂相似；而在治疗时间最长达6年的延长期研究中，维臻高(R)也未出现与生长激素日制剂不同的、新的不良反应类型。余教授谈到，生长激素日制剂在生长激素缺乏症患儿中已有超过40年的使用经验，其安全性特已被临床医生熟知并掌握，基于明确的研究数据，维臻高(R)与日制剂一致的安全性表现，显然也为医生的应用提供了更充分的保障。1.4 储存与使用的便利性突破维臻高(R)在不含防腐剂情况下，室温（≤30℃）可储存6个月，在2-8℃条件下可存储5年，是唯一可在室温下长期存放的生长激素。余文教授强调："这是我们当时完全没有想到的效期，并且清楚的写在说明书中。"这一特性对需要携带药物出行、参加夏令营的家庭至关重要。1.5 注射体验的创新设计维臻高(R)配备电子自动注射笔，由Phillips-Medisize公司生产，2022-2023年获欧洲和美国三项工业设计大奖（PDA 药物递送创新奖、PharmaPack 给药与包装创新奖、红点工业设计奖）。其特点包括：- 单按钮开关，药物复溶与注射全自动完成- 隐形针头设计，患儿看不到针，减少心理恐惧- 配合固定剂量双腔预充笔芯，注射前无需调节剂量，同时避免浪费- 每月4支笔芯+6支针头的一体化包装二、市场策略：技术与临床优势下的差异化商业路径2.1 定价逻辑：突出产品差异化，以技术优势形成产品价值优势维昇药业首席商务官陈军表示：维臻高(R)的年治疗费将会于产品上市时最终确定，但一定会显著高于其他长效生长激素纳入医保后的价格。但这一定价并非简单的"高端溢价"，而是基于三重锚定：- 价值锚定：产品具备"天然结构+优效+室温保存"三重独特属性，维臻高(R)作为长效生长激素迭代产品，产品的独特优势赋予了其核心定价权，将填补高端市场的真空。- 国际锚定：该产品在欧美获批上市，美国年治疗费用50-60万元，维臻高(R)以其"技术优势+临床优势+欧美品质"为背书，将临床需求和价值锚点与国际接轨。- 长期健康价值锚定：生长激素治疗具有明确的时间窗口和长期获益特征。其价值并不取决于单一年度的费用比较，而在于对终身身高结局、心理健康与社会功能的长期改善。从全周期视角衡量，该治疗所带来的健康收益与成本投入之间具有清晰、可解释的价值逻辑。这一策略的风险在于支付能力，但维昇药业的判断是：生长激素市场90%以上为自费，80%以上销售发生在私立医院。2.2 渠道布局：合纵连横的"作战地图"维昇药业作为初创企业，选择了"轻资产、重合作"的扩张路径：- 推广端：与安科生物强强联手，其高级副总裁姚建平表示，公司在生长激素领域深耕27年，以学术触达95%的生长激素KOL专家。此次与维昇药业的合作，"27年经验+划时代产品"将形成前所未有的商业化布局。双方将按地域区隔运营，维昇药业自营沿海核心市场，安科生物负责其余广阔区域，实现市场的全面覆盖。- 流通端：上药控股作为进口分销平台，依托其成熟的供应链体系，提供从通关到终端的全程服务。上药控股副总经理宋潞潞指出，维臻高(R)是其经销的大分子生物药中，唯一不含防腐剂且可常温保存6个月的产品，"这两个优势在对药品商业化成功，特别是儿童用药的商业化成功方面，至关重要"。- 诊疗端：与和睦家、小苹果、卓正等高端私立医院建立深度合作，构建"筛查-诊疗-管理"的全流程闭环。上海和睦家医院长宁院区执行院长刘晓龙表示，其患者群体对"技术领先、长期安全"的产品需求明确，维臻高(R)的核心优势与该群体需求高度匹配，具备良好的临床土壤。- 流量端：患者及家庭在疾病认知与治疗决策过程中，主要通过内容社区、AI 搜索工具及合规的互联网医疗平台获取相关科普信息，逐步形成以专业性、可及性和合规性为核心的患者信息入口，让优质医疗信息精准触达目标人群。三、团队建设：用近乎苛刻的标准筛选最强执行者维昇药业销售与商业运营副总裁潘海风详细介绍了团队建设的"高强度、严标准"体系：- 招聘标准：一线商业化团队中，约20%具备硕士学历，80%为医药相关本科背景；近三分之一来自其他公司的地区经理级别，整体商业化人员结构和行业经验显著高于行业平均水平。- 考核机制：全员"日考+周考+月考"，内容涵盖产品知识、竞品知识、临床医学、疾病知识；每日考试须达90分以上，集训落地考不合格者原机遣返，以严苛的考核标准保障团队的专业能力，确保用人标准与产品价值相一致。- 提前布局：公司提前规划、前置投入，产品上市前6个月商业化团队已90%到岗，为产品上市后的快速市场推进做好了充分准备，体现出公司对商业化执行的前置投入与系统规划。四、其他Q&A环节：问题一：在目前的定价水平下，维臻高(R)的利润率表现如何？未来随着地产化推进，盈利空间如何展望？ 回答： 公司坚持"先上市、先可及"的策略，进口阶段的毛利率足够产品上市早期的推广。随着两年多后实现地产化生产，即便在当前价格水平大幅下降的情况下，毛利率仍有望达到80%以上。从进口到地产化的路径清晰，随着市场规模的持续放量，盈利能力将随规模放量持续改善。问题二：维臻高(R)在公立医院与民营医院中的销售场景如何落地？在部分长效生长激素已进入国谈的背景下，公司如何发挥差异化优势？ 回答： 公司将覆盖三类渠道：公立医院院内、公立医院处方外配及民营医院。受国谈因素影响，公立院内并非未来主战场，核心增长将来自处方外配及民营医疗体系。同时，国家层面已明确提出要有序推进医师多机构执业，鼓励医师依法开展多点执业，医生在公立医院与民营医疗机构之间的执业流动性持续提升。这一趋势为创新、差异化产品在院外及民营场景中的推广和规范使用创造了有利条件。公司将基于这一制度环境，在所有合规场景中积极布局。问题三：除维臻高(R)外，公司其他管线在未来几年的上市节奏及协同贡献如何？ 回答： 公司在内分泌领域已布局多条管线，其中针对甲状旁腺功能减退的帕罗培特立帕肽已分别于2024年年初和年底在欧盟跟美国获批；第三个品种那韦培肽这个月底迎来其 PDUFA 日期，后续产品在中国的上市节奏有望加快。多产品协同放量后，公司整体规模有望持续跃升，长期目标是打造内分泌与代谢领域具备国际竞争力的百亿级创新药企。问题四：已使用短效生长激素的患者，是否可以无缝切换至维臻高(R)？是否有相关临床证据支持？ 回答： 国际3期试验有一个关于日制剂转换为隆培生长激素的研究。研究显示，对于平均使用日制剂已有1.14年、平均剂量为0.29 mg/kg/周的患者，转为隆培生长激素0.24mg/kg/周后，仍然保持了非常良好的追赶生长的趋势。这一研究结果证明了由日制剂转为隆培促生长素每周一次治疗仍可保持非常良好的生长趋势和疗效。问题五：维臻高(R)在长期使用方面的疗效和安全性表现如何？ 回答： 在国际3期试验的延长期实验中，患者平均治疗4.3年、最长达6年，期间患者身高持续改善，部分患者最终身高SDS甚至超过父母平均身高SDS，充分体现了产品在长期治疗中的有效性、安全性及稳定性。问题六：公司目前商业化团队建设情况如何？与安科生物的合作如何推进？ 回答： 公司首年商业化团队已基本到位，团队人员以业内资深骨干为主，强调高专业度、强培训与严格考核。区域运营上，维昇负责沿海一线重点城市，安科覆盖其他区域，双方执行统一学术与培训标准，形成"强强联合"的销售体系，共同推进产品的市场落地。五、长期展望：从单一产品到平台价值维昇药业执行董事兼首席执行官卢安邦在交流结束的致辞中描绘了公司长期发展的蓝图：维臻高(R)的获批意味着TransCon技术平台继FDA和EMA后获NMPA认可，为后续产品铺平道路。在研的帕罗培特立帕肽（甲状旁腺功能减退症）2024年美欧获批后首年销售近40亿人民币，那韦培肽（软骨发育不全）针对中国1万患儿的治疗刚需。"2026-2028是公司"十年磨一剑"的决战期，"卢安邦表示，"我们要验证从临床、注册、准入到商业化的端到端能力，最终成为内分泌代谢领域的百亿级领军企业。"本文基于2026年2月2日维昇药业投资者交流会纪要整理，内容仅供信息参考，不构成投资建议。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - February 23, 2026) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to announce that the Company has entered into an advertising services agreement (the "Agreement") dated February 19, 2026 with AJO Capital Inc. ("AJO"), whereby AJO will provide marketing and investor awareness services to raise public awareness of GMG, including without limitation, original news articles, podcast and interview content creation, newspaper, television, radio and industry network distribution, as well as social media support (the "Services"). GMG has agreed to a monthly payment of US$26,500 for the provision by AJO of the Services. The Agreement commenced on February 19, 2026 and has an initial term of four (4) months unless earlier terminated. The Agreement may be renewed upon mutual written agreement at least thirty (30) days prior to the expiration of the initial term, subject to any modifications to compensation and payment terms as the parties may agree.AJO is a private company based in New York, United States dedicated to providing financial information and media and communication services. The Company will not issue any securities of the Company to AJO as compensation. To the Company's knowledge, AJO and its directors and officers are arm's length from the Company and do not have any interest, direct or indirect, in the Company or its securities nor do they have any right to acquire such an interest.About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information, please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward-looking statements", are not historical facts, are made as of the date of this news release and include without limitation, services to be provided by AJO, term and termination of the Agreement and compensation payable to AJO pursuant to the Agreement.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, assumptions regarding the services to be provided by AJO, covenants by AJO under the Agreement, length of the term of the Agreement, termination of the Agreement and compensation payable to AJO pursuant to the Agreement, that the Company will not issue any future securities to AJO as compensation under the Agreement, that AJO acts at arm's length to the Company and none of AJO, its directors nor officers have any direct or indirect interest in the Company and its securities nor do they have any right to acquire such interests. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation, failure by AJO to render services in accordance with the Agreement, breach of the Agreement by either parties, early termination of the Agreement and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285033 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com